Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 37 to 46 of 46 entries
Sorted by: Best Match Show Resources per page
Is there a rational basis for cannabinoids research and development in ocular pain therapy? A systematic review of preclinical evidence.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Scuteri D, Rombolà L, Hamamura K, Sakurada T, Watanabe C, Sakurada S, Guida F, Boccella S, Maione S, Gallo Afflitto G, Nucci C, Tonin P, Bagetta G, Corasaniti MT.
PMID: 34891121
Biomed Pharmacother. 2021 Dec 07;146:112505. doi: 10.1016/j.biopha.2021.112505. Epub 2021 Dec 07.

BACKGROUND: Purpose of the present systematic review is to investigate preclinical evidence in favor of the working hypothesis of efficacy of cannabinoids in ocular pain treatment.METHODS: Literature search includes the most relevant repositories for medical scientific literature from inception...

Cite
Scuteri D, Rombolà L, Hamamura K, et al. Is there a rational basis for cannabinoids research and development in ocular pain therapy? A systematic review of preclinical evidence. Biomed Pharmacother. 2021;146:112505doi: 10.1016/j.biopha.2021.112505.
Scuteri, D., Rombolà, L., Hamamura, K., Sakurada, T., Watanabe, C., Sakurada, S., Guida, F., Boccella, S., Maione, S., Gallo Afflitto, G., Nucci, C., Tonin, P., Bagetta, G., & Corasaniti, M. T. (2021). Is there a rational basis for cannabinoids research and development in ocular pain therapy? A systematic review of preclinical evidence. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 146112505. https://doi.org/10.1016/j.biopha.2021.112505
Scuteri, D, et al. "Is there a rational basis for cannabinoids research and development in ocular pain therapy? A systematic review of preclinical evidence." Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie vol. 146 (2021): 112505. doi: https://doi.org/10.1016/j.biopha.2021.112505
Scuteri D, Rombolà L, Hamamura K, Sakurada T, Watanabe C, Sakurada S, Guida F, Boccella S, Maione S, Gallo Afflitto G, Nucci C, Tonin P, Bagetta G, Corasaniti MT. Is there a rational basis for cannabinoids research and development in ocular pain therapy? A systematic review of preclinical evidence. Biomed Pharmacother. 2021 Dec 07;146:112505. doi: 10.1016/j.biopha.2021.112505. Epub 2021 Dec 07. PMID: 34891121.
Copy Download .nbib Format: NLM
Efficacy of Essential Oils in Pain: A Systematic Review and Meta-Analysis of Preclinical Evidence.

Frontiers in pharmacology

Scuteri D, Hamamura K, Sakurada T, Watanabe C, Sakurada S, Morrone LA, Rombolà L, Tonin P, Bagetta G, Corasaniti MT.
PMID: 33732159
Front Pharmacol. 2021 Mar 01;12:640128. doi: 10.3389/fphar.2021.640128. eCollection 2021.

No abstract available.

Cite
Scuteri D, Hamamura K, Sakurada T, et al. Efficacy of Essential Oils in Pain: A Systematic Review and Meta-Analysis of Preclinical Evidence. Front Pharmacol. 2021;12:640128doi: 10.3389/fphar.2021.640128.
Scuteri, D., Hamamura, K., Sakurada, T., Watanabe, C., Sakurada, S., Morrone, L. A., Rombolà, L., Tonin, P., Bagetta, G., & Corasaniti, M. T. (2021). Efficacy of Essential Oils in Pain: A Systematic Review and Meta-Analysis of Preclinical Evidence. Frontiers in pharmacology, 12640128. https://doi.org/10.3389/fphar.2021.640128
Scuteri, Damiana, et al. "Efficacy of Essential Oils in Pain: A Systematic Review and Meta-Analysis of Preclinical Evidence." Frontiers in pharmacology vol. 12 (2021): 640128. doi: https://doi.org/10.3389/fphar.2021.640128
Scuteri D, Hamamura K, Sakurada T, Watanabe C, Sakurada S, Morrone LA, Rombolà L, Tonin P, Bagetta G, Corasaniti MT. Efficacy of Essential Oils in Pain: A Systematic Review and Meta-Analysis of Preclinical Evidence. Front Pharmacol. 2021 Mar 01;12:640128. doi: 10.3389/fphar.2021.640128. eCollection 2021. PMID: 33732159; PMCID: PMC7957371.
Copy Download .nbib Format: NLM
Is there a rational basis for cannabinoids research and development in ocular pain therapy? A systematic review of preclinical evidence.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Scuteri D, Rombolà L, Hamamura K, Sakurada T, Watanabe C, Sakurada S, Guida F, Boccella S, Maione S, Gallo Afflitto G, Nucci C, Tonin P, Bagetta G, Corasaniti MT.
PMID: 34891121
Biomed Pharmacother. 2021 Dec 06;146:112505. doi: 10.1016/j.biopha.2021.112505. Epub 2021 Dec 06.

BACKGROUND: Purpose of the present systematic review is to investigate preclinical evidence in favor of the working hypothesis of efficacy of cannabinoids in ocular pain treatment.METHODS: Literature search includes the most relevant repositories for medical scientific literature from inception...

Cite
Scuteri D, Rombolà L, Hamamura K, et al. Is there a rational basis for cannabinoids research and development in ocular pain therapy? A systematic review of preclinical evidence. Biomed Pharmacother. 2021;146:112505doi: 10.1016/j.biopha.2021.112505.
Scuteri, D., Rombolà, L., Hamamura, K., Sakurada, T., Watanabe, C., Sakurada, S., Guida, F., Boccella, S., Maione, S., Gallo Afflitto, G., Nucci, C., Tonin, P., Bagetta, G., & Corasaniti, M. T. (2021). Is there a rational basis for cannabinoids research and development in ocular pain therapy? A systematic review of preclinical evidence. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 146112505. https://doi.org/10.1016/j.biopha.2021.112505
Scuteri, D, et al. "Is there a rational basis for cannabinoids research and development in ocular pain therapy? A systematic review of preclinical evidence." Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie vol. 146 (2021): 112505. doi: https://doi.org/10.1016/j.biopha.2021.112505
Scuteri D, Rombolà L, Hamamura K, Sakurada T, Watanabe C, Sakurada S, Guida F, Boccella S, Maione S, Gallo Afflitto G, Nucci C, Tonin P, Bagetta G, Corasaniti MT. Is there a rational basis for cannabinoids research and development in ocular pain therapy? A systematic review of preclinical evidence. Biomed Pharmacother. 2021 Dec 06;146:112505. doi: 10.1016/j.biopha.2021.112505. Epub 2021 Dec 06. PMID: 34891121.
Copy Download .nbib Format: NLM
New Trends in Migraine Pharmacology: Targeting Calcitonin Gene-Related Peptide (CGRP) With Monoclonal Antibodies.

Frontiers in pharmacology

Scuteri D, Adornetto A, Rombolà L, Naturale MD, Morrone LA, Bagetta G, Tonin P, Corasaniti MT.
PMID: 31024319
Front Pharmacol. 2019 Apr 09;10:363. doi: 10.3389/fphar.2019.00363. eCollection 2019.

Migraine is a common neurologic disorder characterized by attacks consisting of unilateral, throbbing headache accompanied by photophobia, phonophobia, and nausea which remarkably reduces the patients' quality of life. Not migraine-specific non-steroidal anti-inflammatory drugs (NSAIDs) are effective in patients affected...

Cite
Scuteri D, Adornetto A, Rombolà L, et al. New Trends in Migraine Pharmacology: Targeting Calcitonin Gene-Related Peptide (CGRP) With Monoclonal Antibodies. Front Pharmacol. 2019;10:363doi: 10.3389/fphar.2019.00363.
Scuteri, D., Adornetto, A., Rombolà, L., Naturale, M. D., Morrone, L. A., Bagetta, G., Tonin, P., & Corasaniti, M. T. (2019). New Trends in Migraine Pharmacology: Targeting Calcitonin Gene-Related Peptide (CGRP) With Monoclonal Antibodies. Frontiers in pharmacology, 10363. https://doi.org/10.3389/fphar.2019.00363
Scuteri, Damiana, et al. "New Trends in Migraine Pharmacology: Targeting Calcitonin Gene-Related Peptide (CGRP) With Monoclonal Antibodies." Frontiers in pharmacology vol. 10 (2019): 363. doi: https://doi.org/10.3389/fphar.2019.00363
Scuteri D, Adornetto A, Rombolà L, Naturale MD, Morrone LA, Bagetta G, Tonin P, Corasaniti MT. New Trends in Migraine Pharmacology: Targeting Calcitonin Gene-Related Peptide (CGRP) With Monoclonal Antibodies. Front Pharmacol. 2019 Apr 09;10:363. doi: 10.3389/fphar.2019.00363. eCollection 2019. PMID: 31024319; PMCID: PMC6465320.
Copy Download .nbib Format: NLM
Opioids in Post-stroke Pain: A Systematic Review and Meta-Analysis.

Frontiers in pharmacology

Scuteri D, Mantovani E, Tamburin S, Sandrini G, Corasaniti MT, Bagetta G, Tonin P.
PMID: 33424596
Front Pharmacol. 2020 Nov 27;11:587050. doi: 10.3389/fphar.2020.587050. eCollection 2020.

No abstract available.

Cite
Scuteri D, Mantovani E, Tamburin S, et al. Opioids in Post-stroke Pain: A Systematic Review and Meta-Analysis. Front Pharmacol. 2020;11:587050doi: 10.3389/fphar.2020.587050.
Scuteri, D., Mantovani, E., Tamburin, S., Sandrini, G., Corasaniti, M. T., Bagetta, G., & Tonin, P. (2020). Opioids in Post-stroke Pain: A Systematic Review and Meta-Analysis. Frontiers in pharmacology, 11587050. https://doi.org/10.3389/fphar.2020.587050
Scuteri, Damiana, et al. "Opioids in Post-stroke Pain: A Systematic Review and Meta-Analysis." Frontiers in pharmacology vol. 11 (2020): 587050. doi: https://doi.org/10.3389/fphar.2020.587050
Scuteri D, Mantovani E, Tamburin S, Sandrini G, Corasaniti MT, Bagetta G, Tonin P. Opioids in Post-stroke Pain: A Systematic Review and Meta-Analysis. Front Pharmacol. 2020 Nov 27;11:587050. doi: 10.3389/fphar.2020.587050. eCollection 2020. PMID: 33424596; PMCID: PMC7793939.
Copy Download .nbib Format: NLM
High conductivity of ultrathin nanoribbons of SrRuO.

Scientific reports

Falsetti E, Kalaboukhov A, Nucara A, Ortolani M, Corasaniti M, Baldassarre L, Roy P, Calvani P.
PMID: 30315227
Sci Rep. 2018 Oct 12;8(1):15217. doi: 10.1038/s41598-018-33632-3.

SrRuO

Cite
Falsetti E, Kalaboukhov A, Nucara A, et al. High conductivity of ultrathin nanoribbons of SrRuO. Sci Rep. 2018;8(1):15217doi: 10.1038/s41598-018-33632-3.
Falsetti, E., Kalaboukhov, A., Nucara, A., Ortolani, M., Corasaniti, M., Baldassarre, L., Roy, P., & Calvani, P. (2018). High conductivity of ultrathin nanoribbons of SrRuO. Scientific reports, 8(1), 15217. https://doi.org/10.1038/s41598-018-33632-3
Falsetti, E, et al. "High conductivity of ultrathin nanoribbons of SrRuO." Scientific reports vol. 8,1 (2018): 15217. doi: https://doi.org/10.1038/s41598-018-33632-3
Falsetti E, Kalaboukhov A, Nucara A, Ortolani M, Corasaniti M, Baldassarre L, Roy P, Calvani P. High conductivity of ultrathin nanoribbons of SrRuO. Sci Rep. 2018 Oct 12;8(1):15217. doi: 10.1038/s41598-018-33632-3. PMID: 30315227; PMCID: PMC6185982.
Copy Download .nbib Format: NLM
Anxiolytic-Like Effects of Bergamot Essential Oil Are Insensitive to Flumazenil in Rats.

Evidence-based complementary and alternative medicine : eCAM

Rombolà L, Scuteri D, Adornetto A, Straface M, Sakurada T, Sakurada S, Mizoguchi H, Corasaniti MT, Bagetta G, Tonin P, Morrone LA.
PMID: 31485242
Evid Based Complement Alternat Med. 2019 Aug 14;2019:2156873. doi: 10.1155/2019/2156873. eCollection 2019.

Anxiety disorders are one of the most common mental disorders, and benzodiazepines (BDZs), acting on gamma-aminobutyric acid type A (GABA-A) receptor complex, represent the most common antianxiety medications in the world. However, chronic BDZ use elicits several adverse reactions....

Cite
Rombolà L, Scuteri D, Adornetto A, et al. Anxiolytic-Like Effects of Bergamot Essential Oil Are Insensitive to Flumazenil in Rats. Evid Based Complement Alternat Med. 2019;2019:2156873doi: 10.1155/2019/2156873.
Rombolà, L., Scuteri, D., Adornetto, A., Straface, M., Sakurada, T., Sakurada, S., Mizoguchi, H., Corasaniti, M. T., Bagetta, G., Tonin, P., & Morrone, L. A. (2019). Anxiolytic-Like Effects of Bergamot Essential Oil Are Insensitive to Flumazenil in Rats. Evidence-based complementary and alternative medicine : eCAM, 20192156873. https://doi.org/10.1155/2019/2156873
Rombolà, Laura, et al. "Anxiolytic-Like Effects of Bergamot Essential Oil Are Insensitive to Flumazenil in Rats." Evidence-based complementary and alternative medicine : eCAM vol. 2019 (2019): 2156873. doi: https://doi.org/10.1155/2019/2156873
Rombolà L, Scuteri D, Adornetto A, Straface M, Sakurada T, Sakurada S, Mizoguchi H, Corasaniti MT, Bagetta G, Tonin P, Morrone LA. Anxiolytic-Like Effects of Bergamot Essential Oil Are Insensitive to Flumazenil in Rats. Evid Based Complement Alternat Med. 2019 Aug 14;2019:2156873. doi: 10.1155/2019/2156873. eCollection 2019. PMID: 31485242; PMCID: PMC6710760.
Copy Download .nbib Format: NLM
Is there a rational basis for cannabinoids research and development in ocular pain therapy? A systematic review of preclinical evidence.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Scuteri D, Rombolà L, Hamamura K, Sakurada T, Watanabe C, Sakurada S, Guida F, Boccella S, Maione S, Gallo Afflitto G, Nucci C, Tonin P, Bagetta G, Corasaniti MT.
PMID: 34891121
Biomed Pharmacother. 2021 Dec 07;146:112505. doi: 10.1016/j.biopha.2021.112505. Epub 2021 Dec 07.

BACKGROUND: Purpose of the present systematic review is to investigate preclinical evidence in favor of the working hypothesis of efficacy of cannabinoids in ocular pain treatment.METHODS: Literature search includes the most relevant repositories for medical scientific literature from inception...

Cite
Scuteri D, Rombolà L, Hamamura K, et al. Is there a rational basis for cannabinoids research and development in ocular pain therapy? A systematic review of preclinical evidence. Biomed Pharmacother. 2021;146:112505doi: 10.1016/j.biopha.2021.112505.
Scuteri, D., Rombolà, L., Hamamura, K., Sakurada, T., Watanabe, C., Sakurada, S., Guida, F., Boccella, S., Maione, S., Gallo Afflitto, G., Nucci, C., Tonin, P., Bagetta, G., & Corasaniti, M. T. (2021). Is there a rational basis for cannabinoids research and development in ocular pain therapy? A systematic review of preclinical evidence. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 146112505. https://doi.org/10.1016/j.biopha.2021.112505
Scuteri, D, et al. "Is there a rational basis for cannabinoids research and development in ocular pain therapy? A systematic review of preclinical evidence." Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie vol. 146 (2021): 112505. doi: https://doi.org/10.1016/j.biopha.2021.112505
Scuteri D, Rombolà L, Hamamura K, Sakurada T, Watanabe C, Sakurada S, Guida F, Boccella S, Maione S, Gallo Afflitto G, Nucci C, Tonin P, Bagetta G, Corasaniti MT. Is there a rational basis for cannabinoids research and development in ocular pain therapy? A systematic review of preclinical evidence. Biomed Pharmacother. 2021 Dec 07;146:112505. doi: 10.1016/j.biopha.2021.112505. Epub 2021 Dec 07. PMID: 34891121.
Copy Download .nbib Format: NLM
Is there a rational basis for cannabinoids research and development in ocular pain therapy? A systematic review of preclinical evidence.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Scuteri D, Rombolà L, Hamamura K, Sakurada T, Watanabe C, Sakurada S, Guida F, Boccella S, Maione S, Gallo Afflitto G, Nucci C, Tonin P, Bagetta G, Corasaniti MT.
PMID: 34891121
Biomed Pharmacother. 2021 Dec 07;146:112505. doi: 10.1016/j.biopha.2021.112505. Epub 2021 Dec 07.

BACKGROUND: Purpose of the present systematic review is to investigate preclinical evidence in favor of the working hypothesis of efficacy of cannabinoids in ocular pain treatment.METHODS: Literature search includes the most relevant repositories for medical scientific literature from inception...

Cite
Scuteri D, Rombolà L, Hamamura K, et al. Is there a rational basis for cannabinoids research and development in ocular pain therapy? A systematic review of preclinical evidence. Biomed Pharmacother. 2021;146:112505doi: 10.1016/j.biopha.2021.112505.
Scuteri, D., Rombolà, L., Hamamura, K., Sakurada, T., Watanabe, C., Sakurada, S., Guida, F., Boccella, S., Maione, S., Gallo Afflitto, G., Nucci, C., Tonin, P., Bagetta, G., & Corasaniti, M. T. (2021). Is there a rational basis for cannabinoids research and development in ocular pain therapy? A systematic review of preclinical evidence. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 146112505. https://doi.org/10.1016/j.biopha.2021.112505
Scuteri, D, et al. "Is there a rational basis for cannabinoids research and development in ocular pain therapy? A systematic review of preclinical evidence." Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie vol. 146 (2021): 112505. doi: https://doi.org/10.1016/j.biopha.2021.112505
Scuteri D, Rombolà L, Hamamura K, Sakurada T, Watanabe C, Sakurada S, Guida F, Boccella S, Maione S, Gallo Afflitto G, Nucci C, Tonin P, Bagetta G, Corasaniti MT. Is there a rational basis for cannabinoids research and development in ocular pain therapy? A systematic review of preclinical evidence. Biomed Pharmacother. 2021 Dec 07;146:112505. doi: 10.1016/j.biopha.2021.112505. Epub 2021 Dec 07. PMID: 34891121.
Copy Download .nbib Format: NLM
Is there a rational basis for cannabinoids research and development in ocular pain therapy? A systematic review of preclinical evidence.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Scuteri D, Rombolà L, Hamamura K, Sakurada T, Watanabe C, Sakurada S, Guida F, Boccella S, Maione S, Gallo Afflitto G, Nucci C, Tonin P, Bagetta G, Corasaniti MT.
PMID: 34891121
Biomed Pharmacother. 2021 Dec 07;146:112505. doi: 10.1016/j.biopha.2021.112505. Epub 2021 Dec 07.

BACKGROUND: Purpose of the present systematic review is to investigate preclinical evidence in favor of the working hypothesis of efficacy of cannabinoids in ocular pain treatment.METHODS: Literature search includes the most relevant repositories for medical scientific literature from inception...

Cite
Scuteri D, Rombolà L, Hamamura K, et al. Is there a rational basis for cannabinoids research and development in ocular pain therapy? A systematic review of preclinical evidence. Biomed Pharmacother. 2021;146:112505doi: 10.1016/j.biopha.2021.112505.
Scuteri, D., Rombolà, L., Hamamura, K., Sakurada, T., Watanabe, C., Sakurada, S., Guida, F., Boccella, S., Maione, S., Gallo Afflitto, G., Nucci, C., Tonin, P., Bagetta, G., & Corasaniti, M. T. (2021). Is there a rational basis for cannabinoids research and development in ocular pain therapy? A systematic review of preclinical evidence. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 146112505. https://doi.org/10.1016/j.biopha.2021.112505
Scuteri, D, et al. "Is there a rational basis for cannabinoids research and development in ocular pain therapy? A systematic review of preclinical evidence." Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie vol. 146 (2021): 112505. doi: https://doi.org/10.1016/j.biopha.2021.112505
Scuteri D, Rombolà L, Hamamura K, Sakurada T, Watanabe C, Sakurada S, Guida F, Boccella S, Maione S, Gallo Afflitto G, Nucci C, Tonin P, Bagetta G, Corasaniti MT. Is there a rational basis for cannabinoids research and development in ocular pain therapy? A systematic review of preclinical evidence. Biomed Pharmacother. 2021 Dec 07;146:112505. doi: 10.1016/j.biopha.2021.112505. Epub 2021 Dec 07. PMID: 34891121.
Copy Download .nbib Format: NLM
Showing 37 to 46 of 46 entries